A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Related articles:
Related suggestion:
An unusual autumn freeze grips parts of South America, giving Chile its coldest May in 74 yearsLas Vegas Aces sell out a WNBAChina ready to work with Arab countries for higher level community with shared future: XiXi holds welcome ceremony for PutinConservative media personality appointed to seat on Georgia State Election BoardPlane passenger reignites etiquette debate after revealing VERY controversial seat swap trickUN court holds hearing on South Africa's plea against Israel's operations in GazaIn Brazil’s flooded south, a secret mission to recover thousands of gunsUN court holds hearing on South Africa's plea against Israel's operations in GazaInside the Paris hotel that's VERY handy for the Eurostar
3.4231s , 6501.4765625 kb
Copyright © 2024 Powered by Colon cancer blood test offers new screening option ,Global Glance news portal